Welcome to the Synchrony Financial First Quarter 2021 Earnings Conference Call. My name is Vanessa, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded. I will now turn the call over to Jennifer Church, Vice President of Investor Relations. You may begin.

Thank you, and good morning, everyone. Welcome to our quarterly earnings conference call. In addition to today’s press release, we have provided a presentation that covers the topics we plan to address during our call. The press release, detailed financial schedules and presentation are available on our website, synchronyfinancial.com. This information can be accessed by going to the Investor Relations section of the website. Before we get started, I wanted to remind you that our comments today will include forward-looking statements. These statements are subject to risks and uncertainty, and actual results could differ materially. We list the factors that might cause actual results to differ materially in our SEC filings, which are available on our website. During the call, we will refer to non-GAAP financial measures in discussing the company’s performance. You can find a reconciliation of these measures to GAAP financial measures in our materials for today’s call. Finally, Synchrony Financial is not responsible for and does not edit nor guarantee the accuracy of our earnings teleconference transcripts provided by third parties. The only authorized webcasts are located on our website. On the call this morning are Brian Doubles and Brian Wenzel. I will now turn the call over to Brian Doubles.

Thanks, Jennifer, and good morning, everyone. It is truly an honor and a privilege to talk to you today for the first time as the CEO of Synchrony. Building on our strong foundation, I believe Synchrony is exceptionally well-positioned for this next chapter of our growth journey. There is strong momentum in the business driven by the ongoing implementation of our strategy and the unwavering hard work and commitment of our people. While this past year has been challenging and unprecedented in many ways, we are starting to see positive signs of recovery. And we are seeing the benefits of the strategic initiatives that we accelerated in the new programs that we launched last year. I’m very optimistic and excited about the opportunities ahead and I’m honored to lead Synchrony into the future. And with that, I’d like to get into some of the highlights of our first quarter results. Earnings were $1 billion or $1.73 per diluted share an increase of 1.28 over the last year. The resilience of our business has been evident as we navigated the pandemic. From the underlying fundamentals of our business, including diverse programs and networks and solid underwriting to our ability to quickly adapt to meet the moment with easily integrated seamless digital solutions. We have demonstrated that our business is structured to execute even in the most challenging operating environments. And as we begin to emerge from this challenging period, we have seen many of our growth drivers outperform pre-pandemic levels experienced during the first quarter of last year. Importantly, purchase volume increased a strong 8% over last year with a substantial increase in purchase volume per account of 18%. While we’re seeing strong trends on purchase volume, loan receivables were down 7% to $76.9 billion given elevated payment rates with the…

Thanks, Brian, and good morning, everyone. This is an important period of time for our company and the world as we continue to emerge from the pandemic. Our business and the actions we have taken over the past year leave us well-positioned to take advantage of the opportunities, which lie ahead of us. I share Brian’s sentiment of appreciation on the unwavering commitment of our people, I want to thank all those involved in development, delivery and administration of vaccines to help us emerge from this incredibly difficult period of time. I’ll now provide an update on our first quarter results. The pandemic and resultant government stimulus actions have impacted several key areas of our business over the past year. However, our business mix has helped us to mitigate some impact from the pandemic as certain areas have performed very well, including digital, home related products and services, veterinary services, electronics and appliances. Performance in these areas have provided support against the overall effects of the economic downturn as we exit the first quarter, we are starting to see greater signs of economic recovery more broadly. Purchase volume increased 8% versus last year and exceeded our expectations for the quarter. From a macroeconomic perspective, we have seen consumer confidence reach a one-year high in March, unemployment continued to improve and easing of some of the remaining local restrictions. This is evident in the increase in purchase volume per account, which is up 18% over last year. Average active accounts were down 8%, which marks a slowing in the rate of decline, it remains impacted by the macroeconomic effects of pandemic in 2020 and uneven recovery in the first quarter. We did originate over 5 million new accounts, an increase of 3% versus first quarter 2020, which is a positive sign…

Thanks, Brian. I’ll provide a quick overview of key themes for the quarter and then turn it over, so we can begin Q&A. Clearly, the pandemic has had significant impacts and has, in many ways, changed the way we did business. This quarter made it evidence that we are beginning to emerge on other side of this period. Consumer sentiment has improved. The unemployment rate has dropped and U.S. retail posted the largest gain in 10 months. Our business is showing its resilience as growth has accelerated with purchase volume of 8% and 5 million new accounts opened this quarter. And although, the solid growth metrics were tamped down by higher payment rates, which impacted loan receivables and NIM, these are headwinds that we anticipate will soon abate. Credit performance has continued to outperform and we continue to expand our CareCredit network, delivering new products, financing alternatives and experiences with a focus on overall wellness impact. The bottom line is that we demonstrated that we were able to rapidly adapt to operate in a new environment, while continuing to keep our eye on the long-term positioning ourselves well for the future. And in my opinion, we had never been in a stronger position. I’ll now turn the call back to Jennifer to open the Q&A.

That concludes our comments for the quarter. We will now begin the Q&A session, so that we can accommodate as many of you as possible, I’d like to ask the participants to please limit yourself to one primary and one follow-up question. If you have additional questions, the Investor Relations team will be available after the call. Operator, please start the Q&A session.

Thank you. We will now begin our question-and-answer session. [Operator Instructions] And our first question comes from Moshe Orenbuch with Crédit Suisse.

Great. Thanks. Brian, I was hoping that you could talk just a little bit about the – about this return to normalcy with respect to things like late fees and how that’s impacted the net interest margin and the timing, as well as perhaps the prepay speeds, like what are the actual, besides the injections of stimulus, the ongoing effects, like, how should we think about the timeframe for both of those to get back to something approximating normal? Thanks.

Thanks, Moshe, and good morning. So, yes, clearly, we’ve seen the headwind relative to stimulus. We saw the cash flow really start back in mid-March around the [indiscernible] stimulus are started to hit. So from there, we continue to see elevated payments, they’re starting to trend down a little bit now, as we get into latter part of April, obviously, we have a converging factor with tax returns. So stimulus, clearly, is the number one factor. When you think about the late fees, if you went back and looked at our number of delinquent accounts, they’re down over 30% from the 2019 period, so pre-pandemic. So again, as you think about a rising net charge-off or even just the return to normalcy, when you think about the charge-off environment that late fee yield will come back into the book and come in advance of when the charge-offs actually hit. So we would expect to see that yield begin to increase in the back half of the year. What I’d say, Moshe, is lot of people focus on the margins of business. We’re at 14% today. We’ve kind of guided people to, call it, the 16% range in a normalized environment. If you break down the components of that for a second, the first piece is really the excess liquidity, which I started with the stimulus factors, right. So if you went back and looked at excess liquidity pre-pandemic, applied that to the book today, you’ll probably pick up about 90 basis points of net interest margin from there. We previously talked about there’s probably 25 or so basis points, 30 basis points in the benchmark rates, which we’ll see how prime comes. And the residual amount, right, which is the mainly late fee yield and interest yield. We’ll come back into the book and that will rise. So I think you can see a trajectory where this begins to accelerate in the back half of the year and begins to approach normalcy for us as we move into 2022.

Great. And as a follow-up, you mentioned the 5 million new accounts, I’m assuming that’s still with kind of sluggish retail openings. Can that number get better in any update that you can give us on the Verizon and Venmo programs specifically? Thanks.

Yes. Moshe, this is Brian Doubles. I think we would certainly expect that number to continue to grow. We’re not in a fully open economy right now, as you know, I think there’s a lot of reasons to be bullish, when you look at a consumer, you look at the trends on jobs, unemployment back to 6% and then consumer balance sheets are strong and they’re starting to spend again. I think the fact that we saw 8% purchase volume growth and 11% of retail card is a really positive indicator. But that’s not where it should be in a fully functioning open economy. And so I think there’s still room across all the growth metrics to go further from here. We’re still in the early innings in terms of a recovery, but most of the trends that we’re seeing are pretty positive. The fact that we grew purchase volume per account up 18% is a really good indicator that consumers are spending again. And I do think that will turn into more revolving behavior over time. I mean, the effects of the stimulus as Brian said are going to – they’re going to wane over time. I think you’re going to start to see that pretty soon as the confidence gets better, you tend to see consumers take on more debt and revolve a little bit more, which will help on balances and margins as well.

The other thing I’d add Brian, as you think about the new account originations, we haven’t touched the credit box. I do think as we begin to continue to move through the year, we are making credit refinements to expand credit, but we haven’t done that acquisition. So that will also provide a tailwind as we will throughout the year, Moshe.

And then, Moshe, just on Venmo and Verizon, a lot to be excited about on both of those programs. Venmo is still early, but we’re ahead of our expectation in terms of new accounts and spend, the feedback from customers on a card has just been phenomenal. They love the val prop and the fact that it automatically optimizes the rewards for the spending categories, where you’re spending the most. They love the card design, the QR code. So the feedback has just been terrific. And then Verizon, which is a little bit further along, I’d say, we’re seeing really good purchase volume. It’s definitely behaving like a top of wallet card, which is what we wanted. So, so far so good on both and I continue to believe that both can be top 10 programs for us in the future.

Thank you very much.

Thanks, Moshe. Have a good day.

We have our next question from Sanjay Sakhrani with KBW.

Thanks. Good morning. Just wanted to follow-up on the comments on loan growth, I guess, when I think about your framework and outlook for the year. Do you feel like you’re more constructive on loan growth as we look out for the rest of the year? And then just specifically to that offline recovery, are you guys anticipating in offline recovery, because it would seem like it would impact that loan growth more significantly than others.

Yes. Good morning, Sanjay. Yes. As we think about loan growth here, we entered the quarter optimistic and the positioning. As we exited the quarter, we’re probably a bit more optimistic than that. So we’ve seen broad-based recovery, when you look at retail card up 11%, that is both the expansion of digital, as well as some of the, as you call them, offline retailers kind of coming into play. I think from receivable sampling, we are seeing strong volume, some of that is obviously buoyed by the stimulus dollars that came in in March. But we saw strength across each of the months and the quarter. So it outperformed what our expectations are. And as I think about loan growth, I think you probably will see an inflection point here in the second quarter and acceleration into the back part of the year. So I do think you’ll see positivity come through the portfolio. And again, we have the tailwinds that are still existed in the CareCredit platform, right, as you have dental implant services opening up and you still have the supply chain issues in the Payment Solutions platform. So there’s a lot of tailwinds that are in place besides what we’ve already seen. So again, we’re optimistic about where we are and how the second quarter will play out and what we’ve seen to date in the quarter. And then how the back half of the year looks.

Great. And just to follow-up, Brian Doubles, maybe you could just talk a little bit more about the GAAP relationship loss and sort of how you see it affecting the industry as a whole with newer players coming in and possibly doing some aggressive pricing type stuff. I mean, how do you think that affects the future pipeline. And are you seeing deals in your pipeline that look interesting?

Yes. Thanks, Sanjay. Look, I think this was a bit of a unique situation. I’d say, we had a really good partnership for a number of years. We had great feedback actually from the client on our partnership model, our products, our capabilities. And I think at the end of the day, this one just came down to terms and price. And our competition was just a lot more aggressive on both. There were some – I would call them really out of market terms, where they were looking for guaranteed revenue that increased annually regardless of how the program performed. And for context, just given the turnaround that they’ve been working through, the program had been shrinking. And so there’s really only so far, you could go to guarantee those types of payments on a program like that. So, look, we tried to reach an agreement. At the end of the day, there just wasn’t a way for us to get our interests aligned. But I do think this is a pretty unique situation. I look at the pipeline today across all three platforms. We’ve got really attractive opportunities with very strong partners at attractive returns, where our interests are aligned. And I think that is so important. We talked about this for a number of years. We want programs where our interests are aligned in growing the program. We’re doing that in a way that benefits both parties. So I still feel really good about the pipeline as I look across all three platforms.

Thank you.

Great. Thanks, Sanjay. Have a good day.

Our next question is from Ryan Nash with Goldman Sachs.

Hey, good morning guys.

Good morning, Ryan.

So, Brian, you’re running at 17.4% CET1, if I look at this quarter, you’re earned over $1 billion. Reserves are likely coming down. And even with the return of growth, you’re likely to accrete quarter – capital in the coming quarters, even using the existing $1.6 billion buyback. So I was wondering maybe could you just talk about the strategy for getting CET1 back towards peer levels? And is there the potential for you to revisit your capital return as for the coming quarters? Thanks.

Yes. Thanks, Ryan. So, obviously, in the first quarter, we were purchased $200 million of shares in the quarter, that was part of the $1.6 billion we announced in the early part of January. And just to put that frame of reference, obviously, when we went to the board and discuss with the board, that authorization that was in the December timeframe off the models. As we move through the quarter, clearly, we have more information, we’ve updated our scenarios, we submitted our capital plan to the Fed in March and look forward to their feedback later this quarter. So, obviously, we’ll see what the results of that come back, but we’re optimistic with regard to their support for our capital plan. It’s not lost on us, so we have the excess capital Ryan, in the second quarter will again be subject to the limitations by the Fed, which will cap us out around $390 million for the current quarter with regard to the amount of repurchases that we can do. I would make the presumption will be depending upon market conditions at that maximum. And then we’ll be back to you and talk about the capital plan that we submitted back to the Fed. That being said, to the extent that the income profile of the business changes, we have not in that capital plan, dealt anything with GAAP and if that portfolio conveys that we would potentially revisit that and go back to the Fed, if it’s warranted. So we’ll continue those discussions and dialogues with the board and most certainly with our regulators. So there is an opportunity. With regard to your cadence question, clearly, we want to get back to our long-term goal being in line with peers, and we’ll do that as prudently as possible. But obviously, we want to do it with support of all our constituents. They’re not barriers to doing it. We just want to do it in a prudent fashion. And most certainly, we’re not totally done with the pandemic here, but we’ll move as prudently as possible to execute that.

Got it. And maybe just as a Saturday check to follow-up to Moshe’s question. How should we think about the pacing of the NII improvement relative to the pacing of loan growth, given all the dynamics on margin and the normalization of credit over time? As we see these factors abating, should we see NII materially outpacing loan growth as we normalize? Thanks.

Yes. I would probably think the more moving in sequence, as of – in the early part of this quarter. As you get to the back part of the year, when you start seeing the late fee yield come in, you may see the NII accelerate a little bit faster, but it really depend upon that delinquency formation, right.

Got it. Thanks for taking my questions.

Thanks, Ryan.

Thanks, Ryan. Have a good day.

Our next question is from Betsy Graseck with Morgan Stanley.

Hi, good morning.

Good morning.

Good morning, Betsy.

Couple of questions. Just on the capital targets, could you just give us a sense as to where you think optimized is for you over the next cycle here. And part of the reason for the question is, I’m trying to understand how you’re going to be thinking about your capital to fund loan growth. Or on the flip side, do you feel like your loan growth can be fully funded by the liquidity mixed shift. So just give some color there would be helpful. Thanks.

Yes. Let start with the latter part of your question. Clearly, the excess liquidity we have, we believe sustains us with the loan growth that we see coming to the portfolio, which again, gets back to a more normalized level back half of the year, we’ve talked about a potentially acceleration into 2022 as there’s pent up demand. And we believe the excess liquidity is ample enough to support that. And most certainly, with the earnings power of the business that we expect this year from a capital standpoint, we should be able to support it. With regard to the first part of your question, with regard to those targets, I mean, we talk about peer targets, so you think about the cap ones discovers down and that 11 to 12, maybe 10.5 range. We’ll see how the portfolio develops, where we’re optimistic we can get there in a reasonable period of time. I think if you go back, we exited GE with 18%. We made it down to 14% before the pandemic hit. And we think we can get back in a fairly reasonable period of time. And if you remember right before the pandemic hit, we were on a path to execute a $3.6 billion capital plan, where $3.3 billion into it. So we think we can employ it fairly rapidly once we feel comfortable.

Okay. Thanks, Brian. And then, Brian, you’re talking at the beginning of the call about CareCredit. And maybe you could help us understand the impact of the Walgreens portfolio over time. I think you mentioned that you could see Verizon and Venmo getting a top 10 program, maybe you can give us a sense as to how you’re thinking about Walgreens. And then also how should we think about CareCredit impact on RSAs? Is it similar to the way that the retail program is run? Or is there any differences that we should be aware of? Thanks.

Yes. Sure, Betsy. I think, look, CareCredit, I think is probably the most exciting growth opportunity that we’ve got in the company today. And we tried to lay that out for you in a couple of slides. I think first, just going after a market of this size, that’s growing as fast as it is. Obviously, healthcare costs are rising, high deductible plans are increasing in popularity. So less and less as being covered by insurance and that’s really where CareCredit comes in. We’re a big player in the space today, but financing options in this space is still a very small fraction of the potential spend that’s out there. So there is just a ton of room for growth. And I think about the growth and really three components. One is growing the core. We’re in CareCredit accepting about 250,000 locations today. We’re in 40 different specialties. We just entered into 10 new specialties just over the last two years. And we’re in 80% at dental offices, 85% of that. So we’ve got a lot of scale. But with that said, there’s still a lot of room to grow penetration inside of those providers because third-party financing options is still a relatively small percentage. So a lot of room for growth there. And then we talked a little bit about both health systems. We’re in 13 large health systems today. That’s a growing part of our business. We’re paired up with big players like Kaiser Permanente, Cleveland Clinic, and then we talked about pets as really that third leg of the strategy. We’re seeing just unbelievable growth in our pet insurance business that we bought a couple of years ago, up 174% since we bought it. So just a lot to be excited about. And then you touched on Walgreens. We had – our CareCredit cards were accepted at Walgreens. We expanded that relationship to launch a new program and I think similar to Venmo and Verizon, this can be a top 10 program for us. And we’re tapping into 90 million my Walgreens customers. So the opportunity is just huge. And we’re actively working to get that launched in the second half of the year.

Okay. And the RSA – sorry…

So, Betsy, the RSA will operate similar to how you see things operate in the retail card platform. So it would be a similar type of alignment for Walgreens.

Got it. And would you ever go after the opportunity with individual doctor practices for their personal needs? Or is this going to stay at the business level just wondering.

Yes. No. In terms of financing the actual practice, Betsy?

Yes, exactly.

Yes. Yes, that’s an adjacency we’ve looked at. In the past, it’s on the screen, we don’t have any immediate plans to go there, but definitely something to consider in the future.

Okay. Thank you.

Thanks, Betsy. Have a good day.

Our next question is from John Hecht with Jefferies.

Good morning, guys. Thanks for taking my questions. And how are you. I guess, just going a little bit more – it’s clear you did emphasize CareCredit in the prepared remarks. I’m wondering, and you talked about the scale. Maybe can you give us an update I think from a competitive positioning perspective, you’re dramatically larger than the next largest. I mean, maybe you talk about the competitive framework. And just given the growth momentum there, how much bigger as a percentage of, call it, loans or receivables might CareCredit be over the next few years?

Yes, John. We’re certainly probably the biggest player in this space that does what we do. But we have seen competition come and go into the space over time. I love the fact that we have the scale that we have. It’s taken us decades to build this kind of scale and get embedded in 250,000 locations. So I would expect going forward to see outsized growth in CareCredit relative to the rest of the business. So I definitely think this becomes a bigger part of the business going forward. We’re also increasing the level of investment that we’re making in CareCredit. We’ve invested quite a bit, obviously, over the last 10 years. But I’d say just recently with acquisitions and pet insurance. We just recently acquired Allegro Credit. We’re definitely seeing a lot of opportunities to invest both organically and inorganically, which I think will just accelerate the growth rate here relative to the rest of the business.

Okay. And then you guys – you cited some good trends with respect to account adds recently. But clearly, there’s been some churn as there always is in the portfolio. Is there any change in characteristics of where you’re seeing some of the churn come from?

Yes, John, I don’t think we see anything different. Clearly, the opening up of more traditional retail we see an influx there and a little bit through the door population, but there’s no real fundamental shifts.

Okay. Thank you guys very much.

Thanks, John.

Thank you, John. Have a good day.

And we have our next question from Don Fandetti with Wells Fargo.

Hi, good morning. Brian, obviously there has been a big proliferation of fintech companies. And I was just curious as you look at your three businesses, is there one or how would you rank them in terms of where you’re watching closer? And I’d be curious on CareCredit, it seems like that could be susceptible to fintech players maybe more so than other areas, but I could be wrong on that. Just wanted to get your thoughts.

Yes. No, look, I think you can’t limited to just one of the platforms. Obviously, it’s a very competitive space right now. The fintech landscape is changing every minute and we have to stay all over it across all three of our businesses and I think the team is doing a really good job of doing that. So I don’t think that we see of it more acutely in one area than another. I think what we tend to feel from fintech is they tend to do one thing really well and that’s a luxury that they have and we are given our scale. We have to do a lot of things really well to compete with them. But I feel like we’re doing that across all three of our platforms. So the competition is good. At the end of the day, it makes us better. I don’t feel like we’re losing share in any of our three platforms. We still got a lot of opportunity for growth. But it’s something we got to stay all over. Our teams watch this. They’re talking to our partners. And when they see people coming to the space, we’re doing our best to keep amount and solidify our relationship. So I feel really good about our position competitively, but you can never let your guard down, you got to stay all over this.

Yes. And then in terms of not really touching credit underwriting standards, it seems like some of the peers have started to loosen up are you just being cautious or do you still need to see something to get comfortable?

No. So down the way, the way I think about it is, we have started to make refinements in our credit underwriting. If you remember when we started back in the pandemic, we did attaining more on proactive type of credit extension, so we shifted the cut-off down on our private label and dual card product mix. We were reduced a number of proactive credit line increases. We reduced the number of invitation to apply and pre-screen type offers on new accounts. As we move through into 2021, when we started to do in places where we actually have known customers, we begun to unwind a lot of those credit refinements. So we are shifting the cut-offs to more people to get a dual card, which would be a slightly higher line, but it most certainly stimulate some spend in the world. We have begun a number of credit line increase type programs, which are customers that we’ve known and seen credit behavior and payment behavior patterns. And then we’ve also begun to upgrade accounts from private label to dual card that would have qualified for dual card a year ago. So we’re doing a number of things proactively. We just have not touched at the point of acquisition, changed any cut offs, things like that. But again, we didn’t do a lot of that last year. So I don’t really expect us to do a lot of it changes now, but we have begun proactive increases. And the good news is, given our portfolio, we’re able to do that with customers we know and we’re not taking incremental risk in our eyes.

Got it. Thank you.

Thanks, Don. Have a good day.

Our next question is from Rick Shane with J.P. Morgan.

Good morning, guys. Thanks for taking my questions. Look, when we think about the nature of private label, there is more by category concentrated behavior than you would expect to see with, for example, general purpose. When you look forward to where there are opportunities for further recovery, how do you think the portfolio and the opportunity indexes against that?

Yes, Rick. I think probably the best way to think about it is, you have to look at – I know there’s obviously, T&E has a big pullback. We’re a little bit less concentrated there, but certainly our dual cards will benefit from that and our general purpose card will benefit from that. I think the fact that brick and mortar stores are opening again. I think we’re certainly well-positioned to benefit from that. And then I think frankly, the digital trends that we saw over the last year, while we’re going to have some tough comps there coming up over the next few quarters. I feel like some of that shift was certainly permanent and will stay, and we’ll benefit there as well. So look, if you look across the portfolio, the one thing that I think about quite a bit and we hear this from all of our partners, including all the providers in CareCredit is there is a real pent-up demand, right, for pretty much everything, this pent-up desire to spend and get back to normal. We’re talking to our providers in CareCredit. And they can’t keep up with the appointments, because so many people over the last year, they postpone things that weren’t critical. They didn’t want to go into the practices. And now you’re seeing all of that start to flush through. So I think regardless of the category, there is a ton of pent-up desire to spend. And I think if travel and entertainment dining those things come back, I think that also spurs other types of spend that we will see both on our dual cards, but also in some of our adjacencies.

I think it’s also, Brian, as you kind of pointed out, we’re so broad based. When you think about inside retail card, which is up 11% in the first quarter, I mean think about the breadth of lifestyle/specialty groups are there. Think about the not only the American Eagle’s, but the Dick’s Sporting Goods when you got to a value-oriented retailers, such as Sam’s Club, et cetera, TJX, that are in there. We have such a wide breadth of coverage with regard to where spend happens. It actually is a fairly nice tailwind as we come out of this period.

Got it. That’s very helpful. And Brian, you bring up a really interesting point in terms of CareCredit, and it leads to my follow-up question, which is, do you think that there are certain categories of spend that translate naturally into a higher percentage of borrow?

The higher percentage of borrow, is that you said, Rick.

Yes. So for example, people may be more inclined not to borrow on a gas card, but certainly if it’s a larger transaction like you might see through CareCredit there would be more revolve.

Yes. Yes, I know, certainly, we would expect to see that in CareCredit with some of the bigger ticket purchases. We tend to see really good revolve rates there. And I do think it does depend a little bit on the size of the ticket. I mean if somebody is getting braces for their kids that’s a big ticket item. They typically don’t want to tie up their general purpose card utility with that purchase and that’s where CareCredit comes in. And that can be done on a equal pay installment loan, it can be done on a promotional financing product, and we tend to see really good revolve rates there as well.

Great. Thank you guys very much.

Yes. Thanks, Rick.

Thanks, Rick. Have a good day.

And we have our next question from Mihir Bhatia with Bank of America.

Hi, good morning, and thank you for taking my questions. Maybe just to start, I was hoping you could share some color on how you’re currently thinking about just buy now pay later. And I’m thinking more in terms of the PAM4 type program versus some of the larger ticket things like payment solutions, where you basically have a buy now pay later solution. I’m thinking more just the smaller ticket PAM for just how are you thinking about it, is that something you’re considering, should we be expecting you to be in the market with something like that, any timeframes that you can share there? Thanks.

Yes. Look, I can tell you it’s definitely be a product that we offer. We’re going to have something to market with a couple of partners later this year. Just to take a step back more broadly, our strategy is really to provide a full suite of products. We have such a diverse array of partners that we really can have one size fits all strategy. We’ve got to be able to offer revolving products, short-dated installment, longer-term installment, equal pay products, buy now pay later products, and we want to do that in a way that we can bring that full suite of products to our partners, and basically allow them to choose, which products are best for their customers based on, not only their customer, but what types of products are they selling. So not surprisingly bigger ticket items tend to steer more toward the longer-term installment, that can be on a revolving product or closed-end. And then smaller ticket, it tends to be shorter-term either through a product like SetPay or PAM4 type product. So that’s really the strategy to provide that comprehensive suite of products and then take that to our partners and really allow them to select from that menu in terms of what meets their customer needs based on the products that they’re selling in their strategy.

Okay. And any timelines or anything, I guess on the ones that, I just wanted to clarify in terms of just your comments on loan balances, I just wanted to make sure I understood that right. Do you think loan balances have crossed are pretty close to trouping at this point? I guess what I’m asking is, do you see more pressure from payment rates in 2Q or do you think that those balances start increasing from here? And if you’ve seen anything in April that you be willing to share that will be great too. Thank you.

Yes. Thanks, Mihir. So I think, as you think about to be in prior to April, but we continue to see elevated payment rates from historical average that has tended to drill down a little bit. We expect that to burn off during this quarter. So with regard to a loan receivable trough, my expectation would be that we are going to trough here. Most certainly, we have seen very strong sales in the first 20 or so days of April. So our hope would be that we trough here in the second quarter and begin that acceleration up.

Understood. Thank you.

Thank you. Have a good day.

Thank you.

We have our next question from David Scharf with JMP Securities.

Hi, yes, good morning, and thanks for squeezing me in here. Brian, I just had one follow-up on CareCredit. Most questions have been addressed. Can you just provide a little more, maybe granularity or specificity around just how the payment product is marketed, awareness is created for the transitional – transition to more kind of non-elective procedures. I’m just – I’ve seen CareCredit displays at vets the countertops of vets and other elective outlets, but I’m trying to understand how as a member myself of a large healthcare system, how I would even become aware of this is a payment option? How it’s going to be marketed to me?

Yes. A lot of it is, again, we’ve built this business over decades and a lot of it is awareness at the point of sale. So when you’re sitting in the waiting room for – of that appointment or dental appointment, you see the promotional financing offers, you see CareCredit. We actually talk about it in the providers and talk about the benefits of it. And so that’s the primary channel and at least has been historically. We also have a provider locator. And what we’re trying to do is move up funnel a bit, so that at the time that you’re booking your appointment, so a lot of that is now happening online, you’re actually getting – you’re seeing the promotional financing offer. So that that becomes counter part of how you’re thinking about your treatment. So it’s not – once you actually get your appointment, they become aware of it, you can actually go through the whole process well in advance of your appointment and think about how you’re going to pay for whether it’s braces or whatever your treatment is going to be. And we found that to be really successful. So we’ve been building that brand awareness over time. It originated largely inside of a provider’s office, but has certainly expanded to be more digital in nature if through direct marketing and other channels.

Yes. I see, and I believe you may have mentioned MyChart at one point, I mean, once again, just reflecting on particularly over the pandemic the – what expenses over the last few years, yes.

Yes. Getting integrated into the practice management software system is huge for us. That is a really important aspect of the growth strategy here. And for health systems, our integration with Epic inside of the dentists and the vats their practice management software, regardless of what they use we want to be completely integrated there so that it becomes part of the process for the office manager that’s working there. And you can imagine we – with 250,000 providers, we have a wide range of big providers, small providers, and keeping CareCredit top of mind as a payment option is really critical to the future growth of that business.

Got it. And just one last follow-up more program-specific on Venmo I know you had mentioned it. It’s still very early stages and I think you had commented it’s I’m honesty kind of exceeding kind of expectations at this time. Can you give us a little color though on perhaps what percentage of the Venmo user base has initially been targeted? Just trying to get, it’s obviously a very younger-skewing demographic. I got to believe a lot of Venmo users have very thin credit files, just trying to get a sense for how we should think about the opportunity there in terms of the mix of current users.

Yes. I mean, nothing I can provide specifically, but I mean this is a huge opportunity to tap into 70 million Venmo customers. I mean obviously, they have to meet our underwriting criteria and our screen, but that’s just a – it’s a huge opportunity for us. Again, no doubt, this is going to be a top 10 program and the early returns in terms of what we’re seeing on spend and accounts is ahead of what we thought it would be. And we had – we’re pretty aspirational in terms of our expectations. So very positive even though it’s only done in full launch mode for a couple of months.

The only other thing I’d add here, this is another point of the strength that we have, Brian, right, which is the ability to get data from our providers. So when you think about where Venmo may know a customer for a period of time, watched the payment velocity, CLO may be affiliated. They can passes that information. So it actually helps us even though they may have a same credit bureau, the richness of the data they have with PayPal and Venmo maybe a help for us as we underwrite.

Got it. Thank you very much.

Have a good day.

Thanks, David. Vanessa, we have time for one more question.

Thank you. Our last question comes from Dominick Gabriele with Oppenheimer.

Hey, thanks so much for taking my question. If you think about – I just want to go back to the total business and I really appreciate all the color on CareCredit. But if we think about the CET1 and where that can go versus the general purpose players. I think historically, there has been a buffer between private label and general purpose CET1s. And so do you expect that spread to close? And is – have you had conversations with the regulators of them feeling comfortable with that closure? And then I just have a follow-up. Thanks so much.

Yes. Thanks, Dominic. I don’t think we’ve had a conversation with regard to the product private label versus general purpose. I think they look at the loss scenarios that we’ve run, right, the stress scenarios that we’ve run. We all have a very unique feature in the RSAs, which provide a buffer against some of the outlays. So I think when you look at the output of those, we don’t really view it differently than some of our competitors. When you think about a capital one for even take with regard to how their stress capital buffer comes out. So we are in line with those. It’s not really product-oriented. And most certainly for us as we have those conversations really demonstrating to them the resiliency of this business and this customer because of the point of origination. We actually get stronger yields and risk adjusted returns of. And again when you combine that with the RSA buffer, it provides particular strength when it comes to having a lower capital ratio and those are the conversations we’re having with them.

Makes a lot of sense. I would argue, you should be below the general purpose players to some extent because of all those factors on a risk adjusted basis. And then if you think about the efficiency of the business as we move forward, there’s obviously going to be some pressure from multiple factors on the loan book. And obviously, you could see some good cycle growth given the some of the tailwinds of the overall economy. But when we think of GAAP, when we think about all the various factors of just the size of your loan book, how do you think about the long-term efficiency of the business moving forward over the next few years? Is there some pressure on efficiency and so you get back to maybe your more traditional average loan book size? And is there is some dynamics between the credit – CareCredit and the retail card there? Thanks so much. I really appreciate being on the call. Thank you.

Thanks, Dominic. So I think the way to think about efficiency is when we went through last year, we underwent a strategic outlook. That said, if I look out to 2025 think about the mix of business I’m going to have, think about trying to be a top ROA profile company and I look at the revenue characteristics, the loss content characteristics, the RSA characteristics, what is my expense and efficiency ratio have to be in order to be a top tier ROA ahead of all of our peers to really generate the investment thesis. We then roll that back into the plans that we put in place in the latter part of 2020. So I think we’ve engaged upon that. Part of that’s delivering over $210 million of benefit this year from a cost out perspective. I think the greater pressure on the efficiency ratio in the short-term to be honest with you is the revenue headwind that we have with the net interest margin and NII been a little bit impact, that are being impacted by stimulus and it really terrific credit and late fee impact that comes from that. That’s a little bit ahead, but I do think you’re going to see this. This business model, right, we’re built off the foundation of running expenses at a very manageable level given the loan balance side. I think as you see CareCredit’s other business grow, you should be able to get operating leverage, because they run at higher average balances. If you think about the bigger ticket size associated with those accounts. And then what can be loss is the fact that we don’t have to spend as much on marketing as our peers relative to generate those new accounts. So we are an industry probably best or very attractive cost to acquire customers, which really puts us at a competitive advantage versus our peers. So we will tightly manage the efficiency. And while we’re doing this, we’re going to continue to invest in the future. The digital assets that we put in play over the last several years, we’re going to continue to invest for our long-term future. So it’s a combination of investing and really having a business model and set of partners where we can leverage it and generate that operating efficiencies. We probably grow above average with peers and have a higher return than average versus our peers that’s how I would think about it, Dominic.

All right, great. Thanks so much. I really appreciate it.

Great. Have a good day, Dominic.

And thank you. Ladies and gentlemen, this concludes our question-and-answer session. Our call is now concluded. And we thank you for your participation. You may now disconnect.